July 2009
Angion receives IND approval from FDA to start clinical trials in liver fibrosis patients.
June 2009
Angion receives clearance from FDA to start clinical trials in patients with renal disease.
December 2008
Angion completes first in class HGF mimetic Phase IIA clinical trial.
June 2008
Angion’s first-in-class HGF mimetic enters Phase II clinical trial.
December 2007
Angion's first-in-class HGF mimetic completes Phase 1 clinical trial.
October 2007
Angion and The Rogosin Institute, NY ink an agreement to collaborate in the area of renal failure.
April 2007
Angion’s first–in- class HGF mimetic enters a Phase I clinical trial.
January 2007
Angion relocated to a fully integrated BioPharma facility in Garden City, NY. The state-of-the-art facility brings under one roof our molecular modeling, medicinal chemistry and preclinical biology programs.
November 2006
Angion receives an IND approval from FDA to start Phase I clinical trial for its lead HGF mimetic.
September 2006
Angion and Mount Sinai School of Medicine (Scott Friedman, MD), New York, NY are awarded the prestigious National Institutes of Health's (NIH's) Rapid Access to Intervention Development (RAID) program in liver fibrosis.
